Half advice show. Half survival guide. Half absurdity-fest. (Wait, how does this work again? We're not numbers people.) Each episode, we answer all your burning questions, from how to survive a public ...

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...

With more choices and ever-shifting phone plans across the market, we look at two of the big three carriers. Jeff Carlson writes about mobile technology for CNET. He is also the author of dozens of ...